Pharmaceuticals
Abbott Labs Passes Our Test
As it gets the OK for a new rapid Covid-19 detecting device, Abbott Labs could be purchased here following our new technical strategy.
Johnson & Johnson Is Ready to Rally After Reaching a Downside Price Target
While the short-term picture of JNJ suggests more risk is possible, the longer-term patterns are constructive.
3 Japanese Stocks Getting a Boost on Potential Coronavirus Treatments
Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.
Q2 Earnings Expectations, 4 Key Economic Questions, Trading Abbott Labs
I do believe that having no economy is temporary. I also believe that what comes out on the other side will be smaller, far less global.
Sanofi's Charts Show Upside Potential Amid Its Covid-19 Work
The drug and vaccine maker possibly could see its shares double according to a key chart.
3 Strong Long-Term Buys for Uncertain Times
These pharmaceutical names have what it takes amid the current crisis and for the long run.
Good Medicine for a Retest? Johnson & Johnson
A strong S&P for three days makes me leery of what's ahead, but here's an option in JNJ.
Jim Cramer: Here's What Can Be Bought, Sold Right Now
The Holy Grail right now are the few companies thriving and that will keep going after this is over, but there are others who will rebound and some who will not.
Johnson & Johnson Weathers Storm but Needs to Build a New Base
The healthcare giant's charts still show some signs of weakness but also indicate it could rally and make a base from a higher level.
Quidel Soared in Recent Months but More Upside Remains
Traders who are comfortable with risk could consider buying QDEL closer to $85 if available.